U.S. Meibomian Gland Dysfunction Market, By Drug Type (Cyclosporine, Omega-3 supplements, Antibacterial eye drops, Steroids, AZR MD 001, TP 03, NOV03, HY02 - Minocycline), By Route of Administration, By Distribution Channel

PUBLISHED: August 28, 2023

PAGES: 132 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

Description

The U.S. Meibomian Gland Dysfunction market is estimated to be valued at US$ 3,037.5 million in 2023 and is expected to exhibit a CAGR of 15.6% during the forecast period (2023-2030).

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 3,037.5 Mn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	15.60%	2030 Value Projection:	US$ 8,404.4 Mn

U.S. Meibomian Gland Dysfunction Market Share (%), By Drug Type, 2023

U.S. Meibomian Gland Dysfunction Market - IMG1

Meibomian gland dysfunction (MGD) is a term used to describe a group of disorders, both congenital and acquired. Disruption of meibomian gland function negatively impacts both the quality and quantity of meibum secreted, which in turn affects ocular surface health through changes in tear film composition. Increased tear evaporation, hyperosmolarity, inflammation, and ocular surface damage can subsequently occur and cause discomfort, visual disruption, and sensation of dry eyes. The meibomian gland dysfunction market is expected to develop due to the rising demand for coronavirus meibomian gland dysfunctions. Governments and medical regulators accelerated meibomian gland dysfunction development due to the epidemic's severity, even though normal meibomian gland dysfunction development needed years to complete the necessary testing. Factors such as the growing prevalence of infectious diseases, innovative technology in meibomian gland dysfunction development, increased funding from government and international organizations, and the increasing government focus on immunization programs are boosting the market's growth.

Market Dynamics

The key market players are focusing on the adoption of growth and organic strategies such as the launch of new drugs, which is attributed to the growth of the U.S. meibomian gland dysfunctions market. For instance, in January 2021, Kala Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company., launched EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. EYSUVIS is now available in national and regional United States pharmaceutical distribution centers. Patients with a prescription can access EYSUVIS through their local retail pharmacies or home delivery.

Key features of the study:

This report provides an in-depth analysis of the U.S. meibomian gland dysfunction market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the U.S. meibomian gland dysfunction market based on the following parameters-Company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer, inc., AbbVie Inc., Johnson and Johnson Vision Care Inc., Bausch Health Companies Inc., Novartis AG, Santen Pharmaceutical Co., Ltd., I-MED Pharma Inc., OASIS Medical, Sentiss Pharma Pvt. Ltd., RegeneRx, and Akorn, inc. AFT Pharmaceuticals, Alcon Inc., Horus Pharma, Mitotech, Novaliq GmbH, Otsuka Pharmaceutical Co. Ltd, Prestige Consumer Healthcare, Santen Pharmaceutical Co. Ltd, Sun Pharmaceutical Industries Ltd, and VISUfarma.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
U.S. meibomian gland dysfunction market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. meibomian gland dysfunction market

Detailed Segmentation:

U.S. Meibomian Gland Dysfunctions Market, By Drug Type:
- Cyclosporine
- Omega-3 supplements
- Antibacterial Eye Drops
- Steroids
- AZR MD 001
- TP 03
- NOV03 (Novatears)
- HY02 - Minocycline
U.S. Meibomian Gland Dysfunctions Market, By Route of Administration:
- Oral
- Topical
U.S. Meibomian Gland Dysfunction Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Company Profiles
- Pfizer, Inc.
- AbbVie Inc.
- Johnson and Johnson Vision Care Inc.
- Bausch Health Companies Inc.
- Novartis AG
- Santen Pharmaceutical Co., Ltd.
- I-MED Pharma Inc.
- OASIS Medical
- Sentiss Pharma Pvt. Ltd.
- RegeneRx
- Akorn, Inc.
- AFT Pharmaceuticals
- Alcon Inc.
- Horus Pharma
- Mitotech
- Novaliq GmbH
- Otsuka Pharmaceutical Co. Ltd
- Prestige Consumer Healthcare
- Santen Pharmaceutical Co. Ltd
- Sun Pharmaceutical Industries Ltd
- VISUfarma.

Product Code: CMI4186

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Key Developments
Epidemiology
Merger, Acquisition, and Collaboration
Regulatory Scenario
PEST Analysis

4. U.S. Meibomian Gland Dysfunction Market- COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. U.S. Meibomian Gland Dysfunction Market, By Drug Type, 2018-2030 (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Cyclosporine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Omega-3 supplements
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Omega-3 supplements
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Antibacterial Eye Drops
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Steroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
AZR MD 001
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
TP 03
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
NOV03 (Novatears)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
HY02-Minocycline
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

6. U.S. Meibomian Gland Dysfunction Market, By Route of Administration, 2018-2030 (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

7. U.S. Meibomian Gland Dysfunction Market, By Distribution Channel, 2018-2030 (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)